Stoke Therapeutics (STOK) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.93
- EPS estimate
- −$0.80
- EPS surprise
- −16.98%
- Revenue surprise
- +90.70%
- Revenue
- $9.3M
- Revenue estimate
- $4.9M
- Reported
- Aug 3, 2026
Stoke Therapeutics reported Q2 2026 results on August 3, 2026. It posted a loss of $0.93 per share, wider than the $0.80 loss expected, a 16.98% miss. Revenue was $9.3 million, well above the $4.9 million estimate, a 90.70% beat. A year earlier, in Q2 2025, the loss was $0.40 per share on revenue of $13.8 million, so the loss more than doubled and revenue fell about 33%.
Q1 2025 was the only profitable quarter, with EPS of $1.90 on revenue of $158.6 million, far above any other quarter. Otherwise quarterly revenue has stayed between $2.8 million and $22.6 million. Full-year losses narrowed from $2.60 per share in 2022 to $2.37 in 2023 and $1.68 in 2024. Losses have widened again since: the first half of 2026 lost $1.72 per share. Stoke Therapeutics beat the EPS estimate in 13 of the 20 quarters shown. The table has no row for Q4 2025, so full-year 2025 cannot be totalled.
Q3 results came out on November 4, 2025, November 5, 2024 and November 7, 2023. That points to early November 2026 for the next report, which will show whether the wider losses of 2026 persist.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 3, 2026 | −$0.80 | −$0.93 | −16.98% | $9.3M | SEC |
| Q1 2026 | May 7, 2026 | −$0.81 | −$0.79 | +2.17% | $6.2M | SEC |
| Q3 2025 | Nov 4, 2025 | −$0.57 | −$0.65 | −14.40% | $10.6M | SEC |
| Q2 2025 | Aug 12, 2025 | −$0.51 | −$0.40 | +21.88% | $13.8M | SEC |
| Q1 2025 | May 13, 2025 | $0.11 | $1.90 | +1643.12% | $158.6M | SEC |
| Q4 2024 | Mar 18, 2025 | −$0.53 | −$0.18 | +65.92% | $22.6M | SEC |
| Q3 2024 | Nov 5, 2024 | −$0.52 | −$0.47 | +9.62% | $4.9M | SEC |
| Q2 2024 | Aug 7, 2024 | −$0.55 | −$0.46 | +16.07% | $4.8M | SEC |
| Q1 2024 | May 6, 2024 | −$0.61 | −$0.57 | +6.54% | $4.2M | SEC |
| Q4 2023 | Mar 25, 2024 | −$0.61 | −$0.60 | +1.41% | $2.8M | SEC |
| Q3 2023 | Nov 7, 2023 | −$0.63 | −$0.55 | +13.04% | $3.3M | SEC |
| Q2 2023 | Aug 7, 2023 | −$0.63 | −$0.69 | −8.71% | −$2.5M | SEC |
| Q1 2023 | May 4, 2023 | −$0.70 | −$0.53 | +24.38% | $5.2M | SEC |
| Q4 2022 | Mar 6, 2023 | −$0.71 | −$0.65 | +8.84% | $3.3M | SEC |
| Q3 2022 | Nov 14, 2022 | −$0.68 | −$0.66 | +3.55% | $2.9M | SEC |
| Q2 2022 | Aug 8, 2022 | −$0.69 | −$0.63 | +8.38% | $3.2M | SEC |
| Q1 2022 | May 10, 2022 | $0.36 | −$0.66 | −282.37% | $3.0M | SEC |
| Q4 2021 | Mar 10, 2022 | −$0.62 | −$0.66 | −5.87% | $0.00 | SEC |
| Q3 2021 | Nov 8, 2021 | −$0.57 | −$0.61 | −6.94% | $0.00 | SEC |
| Q2 2021 | Aug 10, 2021 | −$0.46 | −$0.60 | −30.15% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Stoke Therapeutics (STOK) last report earnings?
Stoke Therapeutics last reported on Aug 3, 2026, covering fiscal Q2 2026.
Did STOK beat earnings estimates?
No. Stoke Therapeutics reported EPS of −$0.93 for Q2 2026 against a −$0.80 estimate — a 16.98% miss.
How much revenue did STOK report last quarter?
Stoke Therapeutics reported $9.3M in revenue for Q2 2026, against a consensus estimate of $4.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.